APYX news

Results published in Plastic and Reconstructive Surgery show Renuvion significantly increased elastin density and reduced inflammation. CEO Goodwin stated this validates the technology for broader aesthetic use.

Apyx Medical Corporation appointed Stavros Vizirgianakis as Executive Chairman effective June 11, 2026, granting him 450,000 restricted stock units with no cash compensation. The appointment recognizes his service and expected contributions in providing strategic leadership and governance oversight.

Apyx Medical announced publication of clinical study results demonstrating up to 81.8% improvement in cellulite appearance using combined Avéli and Renuvion treatments. The positive data supports the company's surgical aesthetics product portfolio addressing a market affecting up to 90% of post-pube…